Posts From King World News

Einhorn faults unfavorable market conditions for worst month since '08

Hedge fund manager David Einhorn affirmed his approach after July losses tied to Consol Energy Inc., SunEdison Inc. and gold fueled his worst monthly performance since 2008. “The overall market environment has become acutely unfavorable for our investment strategy,” Einhorn said Tuesday in a conference call discussing results at Greenlight Capital Re Ltd., the reinsurer where he is chairman. Einhorn said the investment portfolio dropped about 5.9 percent in July

U.S. DoJ probes Deutsche trades worth billions -source

U.S. DoJ officials have demanded information from Germany’s biggest lender about the transactions because they involved the use of the dollar, the person said. Deutsche Bank declined to comment. It had said in its second-quarter financial report that it was investigating equity trades by Deutsche Bank clients in London and Moscow that offset one another, adding that the volume of these trades was “significant”.

U.S. DoJ probes Deutsche trades worth billions -source

U.S. DoJ officials have demanded information from Germany’s biggest lender about the transactions because they involved the use of the dollar, the person said. Deutsche Bank declined to comment. It had said in its second-quarter financial report that it was investigating equity trades by Deutsche Bank clients in London and Moscow that offset one another, adding that the volume of these trades was “significant”.

Shire Seeks to Cajole Baxalta Into Talks With $30 Billion Offer

Shire Plc made an unsolicited offer to buy one-month-old Baxalta Inc. for about $30 billion in stock to bolster its focus on rare diseases, a move that may fend off larger drugmakers looking at its own assets for a tax break. Shire offered shareholders of Baxalta, a business spun off by Baxter International Inc. last month, about 0.1687 American depositary receipts for each share held, it said in a statement

Shire Seeks to Cajole Baxalta Into Talks With $30 Billion Offer

Shire Plc made an unsolicited offer to buy one-month-old Baxalta Inc. for about $30 billion in stock to bolster its focus on rare diseases, a move that may fend off larger drugmakers looking at its own assets for a tax break. Shire offered shareholders of Baxalta, a business spun off by Baxter International Inc. last month, about 0.1687 American depositary receipts for each share held, it said in a statement